FDA Challenged to Keep Up With ALS Therapies
Former FDAer Peter Pitts, now president of the Center for Medicine in the Public Interest, writes that ALS (amyotrophic lateral sclerosis) “has become an important stress test for whether American regulatory institutions can adapt to 21st century biomedical science.” Writing in an open-source article in the Journal of the Academy of Public Health, Pitts says that the discussion extends beyond any single therapy or sponsor to touch broader questions involving administrative consistency, evidentiary flexibility, patient autonomy, and the future competitiveness of the American biotechnology sector.
“The larger issue is no longer whether regulatory modernization is necessary,” Pitts says. “That debate has largely been settled. The issue now is whether review culture and operational decision-making will evolve quickly enough to keep pace with scientific reality.”
He says questions about ALS therapies reflect a larger issue — whether FDA can apply modern scientific tools consistently when therapies fall outside conventional pharmaceutical models.
He notes that other countries are already answering that question more aggressively. Japan has implemented conditional approval structures for regenerative medicine products, he writes, while China continues investing heavily in cell therapy infrastructure and expedited translational pathways. Likewise, he writes, South Korea and Singapore have adopted similarly adaptive frameworks. “While FDA debates evidentiary philosophy,” he says, “competitors are building industries.”
Pitts’ article covers the strategic importance of regenerative medicine; financial oversight and the realities of innovation; special protocol assessments and scientific legitimacy; statistical orthodoxy and the challenges of heterogeneous disease; biomarkers, accelerated approval, and regulatory consistency; procedural fairness and advisory committee integrity; the ACT for ALS and the implementation gap; ethics and the human cost of delay; rebuilding confidence in regulatory leadership; and comparative regulatory precedents in rare disease and regenerative medicine.
He concludes that FDA has acknowledged much of the transformation through accelerated approvals, RMAT (regenerative medicine advanced therapy) designation, the ACT for ALS (Accelerating Access to Critical Therapies for ALS Act) initiative, and expanded support for innovative trial methodologies. “The remaining challenge is consistency,” Pitts declares. “Future policy decisions will determine whether American regulatory institutions can evaluate these therapies using standards aligned with contemporary biomedical science rather than frameworks inherited largely from another era. The future of rare disease innovation may very well depend on the answer.”